central bank of nigeria digital currency, Reviews

The securities sector fluctuated and strengthened, and the securities sector fluctuated and strengthened. Guosheng Financial Holdings had three consecutive boards, Guolian Securities rose more than 8%, and Harbin Investment Co., Ltd., Huaxin Co., Ltd., Cinda Securities and Southwest Securities followed suit.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Zhejiang has published a list of the top 500 enterprises. According to the news released by Zhejiang in WeChat official account, Zhejiang Institute of Science and Technology Information organized the evaluation of innovation ability of high-tech enterprises, and recently selected the top 500 high-tech enterprises in Zhejiang Province in 2024. Among them, Hangzhou Hikvision Digital Technology Co., Ltd., Ningbo Oaks Electric Co., Ltd. and Xinhua San Technology Co., Ltd. are in the top three.

Baijiayun received $15 million in financing. One-stop AI video technology service provider Baijiayun (NASDAQ：RTC) announced that the company had signed a series of important agreements with YA II PN, Ltd, a fund managed by Yorkville Advisors Global and LP. The company received $15 million in financing, and the down payment of $3 million was received on the signing date of the agreement.Zhengzhou plans to identify three 4A-level scenic spots. On December 12th, it was reported that through the procedures of "voluntary declaration, step-by-step recommendation, landscape review, on-site inspection and party group research", Zhengzhou Municipal Bureau of Culture, Radio, Film and Tourism plans to identify three scenic spots, including Zhongmu Zhengzhou Haichang Ocean Park, Gongyi Qinglong Mountain Ecological Tourism Zone and Guancheng Zhengzhou Shangdu Ancient City Tourist Zone, as national 4A-level tourist attractions. The publicity period is 5 working days from December 9.Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.

The individual pension system has been extended to the whole country. (Xinhua News Agency)In 2024, the qualification examination and approval of the first batch of new materials insurance compensation was started, and the Ministry of Industry and Information Technology recently issued a notice to organize the qualification examination and approval of the first batch of new materials insurance compensation in 2024. It is clear that the enterprise applying for qualification should be an enterprise that produces and manufactures the products listed in the Catalogue for the Demonstration and Guidance of the First Application of Key New Materials (2024 Edition). It belongs to an independent legal person registered in People's Republic of China (PRC), has strong design and development, manufacturing and industrialization capabilities, has a relatively complete team of professional technicians, and has mastered the core technology and intellectual property rights of this product development. The qualification examination and approval procedures need to go through three steps: enterprise declaration, review by local industrial and information authorities or recommended units such as the central enterprise group, and expert review organized by the Ministry of Industry and Information Technology. After review, the product compensation qualification is determined, and the amount of subsidy funds is approved according to a certain proportion of the product value, and the effective period is no more than 3 years.Zou Yingguang, General Manager of CITIC Securities: It is expected that the demand for cross-border investment and financing at home and abroad will be further released. At the investor open day of CITIC Securities in 2024, Zou Yingguang, General Manager of CITIC Securities, said that the demand for two-way cross-border investment and financing is very strong, whether it is a China enterprise "going abroad" or an overseas investor "coming to China". Among them, with the rapid evolution of China's new open economic system, cross-border finance will usher in greater development space, and securities companies will be in cross-border finance. In the medium and long term, China's macro securitization rate is still accelerating, the internationalization of Chinese-funded enterprises will continue to increase, and the opening up of China's capital market will continue to increase. It is expected that the demand for cross-border investment and financing from domestic and foreign customers will be further released.